NASDAQ:PRTK Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.65 -0.04 (-2.37%) (As of 03/24/2023 08:51 PM ET) Add Compare Share Share Today's Range$1.62▼$1.7150-Day Range$1.37▼$2.4052-Week Range$1.29▼$3.65Volume465,000 shsAverage Volume485,104 shsMarket Capitalization$94.48 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Paratek Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside1,112.1% Upside$20.00 Price TargetShort InterestBearish7.91% of Float Sold ShortDividend StrengthN/ASustainability-2.98Upright™ Environmental ScoreNews Sentiment-0.26Based on 7 Articles This WeekInsider TradingSelling Shares$13,300 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.97) to $0.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.12 out of 5 starsMedical Sector985th out of 1,005 stocksPharmaceutical Preparations Industry475th out of 486 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Paratek Pharmaceuticals has a forecasted upside of 1,112.1% from its current price of $1.65.Amount of Analyst CoverageParatek Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.91% of the float of Paratek Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverParatek Pharmaceuticals has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Paratek Pharmaceuticals has recently increased by 1.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreParatek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.Environmental SustainabilityThe Environmental Impact score for Paratek Pharmaceuticals is -2.98. Previous Next 1.0 News and Social Media Coverage News SentimentParatek Pharmaceuticals has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Paratek Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for PRTK on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Paratek Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,300.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions41.90% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Paratek Pharmaceuticals are expected to grow in the coming year, from ($0.97) to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Paratek Pharmaceuticals (NASDAQ:PRTK) StockParatek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.Read More Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTK Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comParatek Pharmaceuticals, Inc. Forecasted to Earn Q1 2023 Earnings of ($0.27) Per Share (NASDAQ:PRTK)March 20, 2023 | americanbankingnews.comHC Wainwright Lowers Paratek Pharmaceuticals (NASDAQ:PRTK) Price Target to $10.00March 26, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 18, 2023 | seekingalpha.comParatek Pharmaceuticals, Inc. (PRTK) Q4 2022 Earnings Call TranscriptMarch 18, 2023 | finance.yahoo.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | msn.comParatek Pharmaceuticals Earnings Perspective: Return On Capital EmployedMarch 17, 2023 | finance.yahoo.comQ4 2022 Paratek Pharmaceuticals Inc Earnings CallMarch 16, 2023 | msn.comParatek Pharmaceuticals GAAP EPS of -$0.13 misses by $0.23, revenue of $75.6M beats by $12.13MMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 16, 2023 | msn.comParatek Plunges as Projections Dash HopesMarch 16, 2023 | finance.yahoo.comWhy Paratek Pharmaceuticals Stock Is Plunging TodayMarch 16, 2023 | seekingalpha.comParatek stock slumps ~25% despite Q4 revenue beat as FY23 sales outlook below estimatesMarch 16, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 MillionMarch 15, 2023 | benzinga.comParatek Pharmaceuticals Earnings PreviewMarch 8, 2023 | finance.yahoo.comParatek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16February 23, 2023 | finance.yahoo.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) On The Verge Of Breaking EvenJanuary 18, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)January 5, 2023 | finance.yahoo.comParatek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield ContractJanuary 2, 2023 | finance.yahoo.comIndividual investors account for 39% of Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) ownership, while institutions account for 38%December 20, 2022 | finance.yahoo.comParatek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the BoardDecember 19, 2022 | finance.yahoo.comParatek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShieldNovember 21, 2022 | finance.yahoo.comParatek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx ConferenceNovember 9, 2022 | finance.yahoo.comParatek Pharmaceuticals Third Quarter 2022 Earnings: Misses ExpectationsNovember 4, 2022 | seekingalpha.comParatek Pharmaceuticals, Inc. (PRTK) Q3 2022 Earnings Call TranscriptNovember 4, 2022 | finance.yahoo.comParatek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 MillionNovember 4, 2022 | finance.yahoo.comParatek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue EstimatesNovember 1, 2022 | finance.yahoo.comParatek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTK Company Calendar Last Earnings11/08/2021Today3/26/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees207Year Founded1996Price Target and Rating Average Stock Price Forecast$20.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+506.1%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,570,000.00 Net Margins-39.66% Pretax Margin-39.63% Return on EquityN/A Return on Assets-38.31% Debt Debt-to-Equity RatioN/A Current Ratio3.66 Quick Ratio3.22 Sales & Book Value Annual Sales$160.27 million Price / Sales0.59 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.54Miscellaneous Outstanding Shares57,260,000Free Float52,684,000Market Cap$94.48 million OptionableOptionable Beta1.52 Social Links Key ExecutivesEvan LohChief Executive Officer & DirectorAdam WoodrowPresident & Chief Commercial OfficerSarah HigginsVP, Chief Financial & Accounting OfficerRaj PadmanabhanVice President-Information TechnologyPaul McGovernVice President-Clinical & Medical AffairsKey CompetitorsNektar TherapeuticsNASDAQ:NKTRAssembly BiosciencesNASDAQ:ASMBCumberland PharmaceuticalsNASDAQ:CPIXOmerosNASDAQ:OMERVaccitechNASDAQ:VACCView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Sold 16,200 shares on 3/15/2023Ownership: 0.054%NatixisBought 29,006 shares on 2/24/2023Ownership: 0.052%Jeffrey SteinSold 7,000 sharesTotal: $13,300.00 ($1.90/share)B. Riley Wealth Advisors Inc.Sold 16,200 shares on 2/21/2023Ownership: 0.054%AIGH Capital Management LLCBought 269,719 shares on 2/16/2023Ownership: 7.483%View All Insider TransactionsView All Institutional Transactions PRTK Stock - Frequently Asked Questions What is Paratek Pharmaceuticals' stock price forecast for 2023? 0 equities research analysts have issued 1 year price objectives for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $10.00 to $30.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 1,112.1% from the stock's current price. View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts. How have PRTK shares performed in 2023? Paratek Pharmaceuticals' stock was trading at $1.87 at the beginning of the year. Since then, PRTK shares have decreased by 11.8% and is now trading at $1.65. View the best growth stocks for 2023 here. When is Paratek Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our PRTK earnings forecast. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to the consensus estimate of $22.98 million. During the same quarter in the prior year, the business earned ($0.46) earnings per share. What ETFs hold Paratek Pharmaceuticals' stock? ETFs with the largest weight of Paratek Pharmaceuticals (NASDAQ:PRTK) stock in their portfolio include AltShares Event-Driven ET (EVNT) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM). What guidance has Paratek Pharmaceuticals issued on next quarter's earnings? Paratek Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $143.00 million-$158.00 million, compared to the consensus revenue estimate of $232.02 million. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL). What is Paratek Pharmaceuticals' stock symbol? Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK." Who are Paratek Pharmaceuticals' major shareholders? Paratek Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (7.48%), General American Investors Co. Inc. (3.39%), Millennium Management LLC (1.02%), Geode Capital Management LLC (0.84%), CM Management LLC (0.62%) and Renaissance Technologies LLC (0.44%). Insiders that own company stock include Adam Woodrow, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner and William M Haskel. View institutional ownership trends. How do I buy shares of Paratek Pharmaceuticals? Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Paratek Pharmaceuticals' stock price today? One share of PRTK stock can currently be purchased for approximately $1.65. How much money does Paratek Pharmaceuticals make? Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $94.48 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. How many employees does Paratek Pharmaceuticals have? The company employs 207 workers across the globe. How can I contact Paratek Pharmaceuticals? Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039. This page (NASDAQ:PRTK) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.